These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 31136607)

  • 21. Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models.
    Suominen MI; Fagerlund KM; Rissanen JP; Konkol YM; Morko JP; Peng Z; Alhoniemi EJ; Laine SK; Corey E; Mumberg D; Ziegelbauer K; Käkönen SM; Halleen JM; Vessella RL; Scholz A
    Clin Cancer Res; 2017 Aug; 23(15):4335-4346. PubMed ID: 28364014
    [No Abstract]   [Full Text] [Related]  

  • 22. Current approaches to incorporation of radium-223 in clinical practice.
    Parker C; Heidenreich A; Nilsson S; Shore N
    Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):37-47. PubMed ID: 29298991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radium-223 in the treatment of osteoblastic metastases: a critical clinical review.
    Humm JL; Sartor O; Parker C; Bruland OS; Macklis R
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):898-906. PubMed ID: 25832684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
    Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
    Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene expression analysis of bone metastasis and circulating tumor cells from metastatic castrate-resistant prostate cancer patients.
    Cho WJ; Oliveira DS; Najy AJ; Mainetti LE; Aoun HD; Cher ML; Heath E; Kim HR; Bonfil RD
    J Transl Med; 2016 Mar; 14():72. PubMed ID: 26975354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer.
    Nilsson S
    Curr Oncol Rep; 2016 Feb; 18(2):14. PubMed ID: 26779616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radium-223 for the treatment of metastatic castration-resistant prostate cancer: A window of opportunity.
    Gómez-Veiga F; Álvarez-Ossorio JL; Carballido-Rodríguez J; Juárez-Soto A; Rodríguez-Antolín A; Cozar-Olmo JM
    Actas Urol Esp (Engl Ed); 2018 Dec; 42(10):616-624. PubMed ID: 30041891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcomes, management, and treatment patterns in patients with metastatic castration-resistant prostate cancer treated with radium-223 in community compared to academic settings.
    Sartor O; Appukkuttan S; Weiss J; Tsao CK
    Prostate; 2021 Jul; 81(10):657-666. PubMed ID: 33978244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer?
    Dorff TB; Gross ME
    Am Soc Clin Oncol Educ Book; 2015; ():e270-3. PubMed ID: 25993185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.
    Sartor O; Coleman R; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Fosså SD; Chodacki A; Wiechno P; Logue J; Widmark A; Johannessen DC; Hoskin P; James ND; Solberg A; Syndikus I; Vogelzang NJ; O'Bryan-Tear CG; Shan M; Bruland ØS; Parker C
    Lancet Oncol; 2014 Jun; 15(7):738-46. PubMed ID: 24836273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.
    Ryan CJ; Saylor PJ; Everly JJ; Sartor O
    Oncologist; 2014 Oct; 19(10):1012-8. PubMed ID: 25232039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: A real-world evidence multicenter study.
    Hyväkkä A; Kääriäinen OS; Utriainen T; Löyttyniemi E; Mattila K; Reinikainen P; Sormunen J; Jääskeläinen M; Auvinen P; Minn H; Sundvall M
    Cancer Med; 2023 Feb; 12(4):4064-4076. PubMed ID: 36156455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases.
    Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo Perez JM; Wagner V; Li R; Nordquist LT
    Ann Oncol; 2017 Oct; 28(10):2464-2471. PubMed ID: 28961839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radium-223 in Metastatic Castration-Resistant Prostate Cancer: Clinical Development and Use in Contemporary Practice.
    Morgan SC
    J Med Imaging Radiat Sci; 2019 Dec; 50(4S1):S26-S30. PubMed ID: 31231006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223.
    Rodriguez-Vida A; Torregrosa MD; Pinto Á; Climent MÁ; Olmos D; Carles J
    Clin Transl Oncol; 2018 Jun; 20(6):679-686. PubMed ID: 29098556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial.
    Morris MJ; Loriot Y; Sweeney CJ; Fizazi K; Ryan CJ; Shevrin DH; Antonarakis ES; Pandit-Taskar N; Deandreis D; Jacene HA; Vesselle H; Petrenciuc O; Lu C; Carrasquillo JA; Higano CS
    Eur J Cancer; 2019 Jun; 114():107-116. PubMed ID: 31082669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program.
    Saad F; Gillessen S; Heinrich D; Keizman D; O'Sullivan JM; Nilsson S; Miller K; Wirth M; Reeves J; Seger M; Carles J; Heidenreich A
    Clin Genitourin Cancer; 2019 Oct; 17(5):348-355.e5. PubMed ID: 31311763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer.
    van der Doelen MJ; Isaacsson Velho P; Slootbeek PHJ; Pamidimarri Naga S; Bormann M; van Helvert S; Kroeze LI; van Oort IM; Gerritsen WR; Antonarakis ES; Mehra N
    Eur J Cancer; 2020 Sep; 136():16-24. PubMed ID: 32634759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complete Cycles of Radium-223 Improve Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study.
    Yang HC; Chang LW; Li JR; Wang SS; Yang CK; Chen CS; Lu K; Chen CC; Wang SC; Lin CY; Cheng CL; Ou YC; Chiu KY; Hung SC
    Anticancer Res; 2023 Apr; 43(4):1809-1816. PubMed ID: 36974814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A qualitative research study in Japan investigating patients' experience with metastatic castration-resistant prostate cancer: from diagnosis to decision for Ra-223 treatment.
    Akakura K; Uemura H; Miyazaki K; Stroupe A; Seo C; Uzumcu A; Ledesma DA
    Future Oncol; 2021 Dec; 17(36):5103-5118. PubMed ID: 34664992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.